{"id":171767,"date":"2025-10-23T09:02:15","date_gmt":"2025-10-23T13:02:15","guid":{"rendered":"https:\/\/44.250.171.167\/?p=171767"},"modified":"2025-10-23T09:02:15","modified_gmt":"2025-10-23T13:02:15","slug":"laurus-labs-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/laurus-labs-q2-fy26-earnings-results\/","title":{"rendered":"Laurus Labs Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. Presenting below are its Q2 FY26 earnings results.<\/p>\n<p>&nbsp;<\/p>\n<h2 class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0\">Q2 FY26 Earnings Results<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Revenue from Operations:<\/strong>\u00a0\u20b91,653 crore, up\u00a035% YoY\u00a0from \u20b91,224 crore, fueled by strong CDMO and generics performance.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Gross Margin:<\/strong>\u00a0<strong>59.9%<\/strong>, compared with 55.2% YoY, improving by 470 basis points due to favorable product mix and operating leverage benefits.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>EBITDA:<\/strong>\u00a0\u20b9429 crore, up\u00a0136% YoY\u00a0from \u20b9182 crore;\u00a0EBITDA margin\u00a0expanded sharply to\u00a026%\u00a0from 14.9% last year.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Profit Before Tax (PBT):<\/strong> \u20b9270 crore, up from \u20b923 crore YoY, more than 11x growth.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Net Profit (PAT):<\/strong>\u00a0\u20b9195 crore, up\u00a0870% YoY\u00a0from \u20b920 crore (\u20b9195 crore vs \u20b919.8 crore YoY), beating market estimates.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Earnings Per Share (EPS):<\/strong>\u00a0\u20b93.6, up from \u20b90.4 in Q2 FY25, reflecting an 800% increase.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Interim Dividend:<\/strong>\u00a0\u20b90.80 per share declared (record date\u00a0October 31, 2025, payment on or after\u00a0November 12, 2025).\u200b<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0\"><strong>Segmental Performance<\/strong><\/p>\n<div class=\"group relative\">\n<div class=\"w-full overflow-x-auto md:max-w-[90vw] border-subtlest ring-subtlest divide-subtlest bg-transparent\">\n<table class=\"border-subtler my-[1em] w-full table-auto border-separate border-spacing-0 border-l border-t\">\n<thead class=\"bg-subtler\">\n<tr>\n<th class=\"border-subtler p-sm break-normal border-b border-r text-left align-top\">Business Segment<\/th>\n<th class=\"border-subtler p-sm break-normal border-b border-r text-left align-top\">Q2 FY26 Revenue<\/th>\n<th class=\"border-subtler p-sm break-normal border-b border-r text-left align-top\" style=\"text-align: center;\">YoY Growth<\/th>\n<th class=\"border-subtler p-sm break-normal border-b border-r text-left align-top\">Remarks<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\"><strong>CDMO (Contract Development &amp; Manufacturing)<\/strong><\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">\u20b9518 crore<\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">+53%<\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">Continued momentum in late-phase clinical and commercial delivery projects; major growth driver with increasing global clientele\u200b<span class=\"whitespace-nowrap\">.<\/span><\/td>\n<\/tr>\n<tr>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\"><strong>Generics<\/strong><\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">\u20b91,135 crore<\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">+28%<\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">Driven by higher ARV (antiretroviral) volumes and developed market supplies\u200b<span class=\"whitespace-nowrap\">.<\/span><\/td>\n<\/tr>\n<tr>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\"><strong>API (Active Pharmaceutical Ingredients)<\/strong><\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">\u20b9617 crore<\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">+11%<\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">Strong recovery in non-ARV business amid stabilized pricing environment<span class=\"whitespace-nowrap\">\u200b.<\/span><\/td>\n<\/tr>\n<tr>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\"><strong>FDF (Finished Dosage Formulations)<\/strong><\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">\u20b9518 crore<\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">+58%<\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">Growth led by increased production efficiency and new molecule launches<span class=\"whitespace-nowrap\">\u200b.<\/span><\/td>\n<\/tr>\n<tr>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\"><strong>Bio Business<\/strong><\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">\u20b947 crore<\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">+18%<\/td>\n<td class=\"px-sm border-subtler min-w-[48px] break-normal border-b border-r\" style=\"text-align: center;\">Continued expansion in biologics manufacturing supported by partnerships<span class=\"whitespace-nowrap\">\u200b.<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"bg-base border-subtler shadow-subtle pointer-coarse:opacity-100 right-xs absolute bottom-0 flex rounded-lg border opacity-0 transition-opacity group-hover:opacity-100 [&amp;&gt;*:not(:first-child)]:border-subtle [&amp;&gt;*:not(:first-child)]:border-l\">\n<div class=\"flex\"><\/div>\n<div class=\"flex\"><\/div>\n<\/div>\n<\/div>\n<h3 class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0\">Management Commentary<\/h3>\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Dr. Satyanarayana Chava, Founder &amp; CEO, Laurus Labs:<\/strong><br \/>\n\u201cOur Q2 FY26 results <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/7a712afa-c933-4286-ae6a-7c35857aa136.pdf\" target=\"_blank\" rel=\"noopener\">showcase strong growth across all core businesses<\/a>. We continue to maintain leadership in ARVs while advancing our CDMO offerings, which have become a significant revenue contributor. The recently approved land allocation from the Andhra Pradesh government and our planned investments underscore our commitment toward capacity enhancement and adoption of advanced technologies. Our strategic investment in Aarvik Therapeutics gives us access to next-gen\u00a0<strong>Antibody-Drug Conjugate (ADC)<\/strong>\u00a0technology, furthering our integrated drug services ambitions.\u201d.\u200b<\/p>\n<p>&nbsp;<\/p>\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>V.V. Ravi Kumar, CFO:<\/strong><br \/>\n\u201cOur fundamentals remain robust with improved margins and operational efficiencies. The strong top-line growth from CDMO and generics aligns with our goal of sustaining EBITDA margin above 25% going forward.\u201d.\u200b<\/p>\n<p>&nbsp;<\/p>\n<p class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0\"><strong>Strategic Developments<\/strong><\/p>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Expansion Initiatives:<\/strong><\/p>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Land acquired in\u00a0Andhra Pradesh\u00a0for expansion of manufacturing and R&amp;D infrastructure.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\">Strategic investment of\u00a0US$ 2 million\u00a0in Aarvik Therapeutics to enhance ADC capabilities in oncology and immunotherapy pipeline.\u200b<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Margin Outlook:<\/strong>\u00a0Management expects\u00a0EBITDA margin to remain above 24%\u00a0for FY26 supported by higher asset utilization and value-added CDMO operations.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Balance Sheet:<\/strong>\u00a0Strong cash generation supports ongoing CAPEX programs aimed at scaling next-gen biologics and high-potency manufacturing.\u200b<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-171768\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings-839x1024.png\" alt=\"Laurus Labs Q2 FY26 Earnings Results\" width=\"640\" height=\"781\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings.png 1489w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/p>\n<p>&nbsp;<\/p>\n<h2 class=\"mb-2 mt-4 font-display font-semimedium text-base first:mt-0\">Q1 FY26 Earnings Results<\/h2>\n<ul class=\"marker:text-quiet list-disc\">\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>Revenue:<\/strong>\u00a0\u20b91,570 crore, up 31% YoY.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>EBITDA:<\/strong>\u00a0\u20b9389 crore; margin 24.8%.<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>PAT:<\/strong>\u00a0\u20b9163 crore, up 15% QoQ and 710% YoY from the base quarter last year.\u200b<\/p>\n<\/li>\n<li class=\"py-0 my-0 prose-p:pt-0 prose-p:mb-2 prose-p:my-0 [&amp;&gt;p]:pt-0 [&amp;&gt;p]:mb-2 [&amp;&gt;p]:my-0\">\n<p class=\"my-2 [&amp;+p]:mt-4 [&amp;_strong:has(+br)]:inline-block [&amp;_strong:has(+br)]:pb-2\"><strong>EPS:<\/strong>\u00a0\u20b93.0.<\/p>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>To view the company&#8217;s previous earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/lauruslabs\/\">click here<\/a>\u00a0 to visit the Alphastreet India news channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":171768,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[11776,3187],"class_list":["post-171767","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-healthcare-stocks","tag-active-pharmaceutical-ingredients","tag-biotechnology"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/Laurus-Labs-Q2-FY26-Earnings.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":177358,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-q3-fy26-earnings-results\/","url_meta":{"origin":171767,"position":0},"title":"Laurus Labs Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 23, 2026","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Laurus Labs Q3 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-37.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169505,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q1-fy26-earnings-results-a-whopping-1146-rise-in-profits\/","url_meta":{"origin":171767,"position":1},"title":"Laurus Labs Ltd Q1 FY26 Earnings Results &#8211; A whopping 1146% rise in Profits","author":"Chirag Gupta","date":"July 29, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166795,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q3fy25-304-rise-in-profits\/","url_meta":{"origin":171767,"position":2},"title":"Laurus Labs Ltd Q3FY25; 304% rise in Profits","author":"Chirag Gupta","date":"February 11, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/2-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168672,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q4fy25-211-rise-in-profits\/","url_meta":{"origin":171767,"position":3},"title":"Laurus Labs Ltd Q4FY25; 211% rise in Profits","author":"Chirag Gupta","date":"June 5, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/3-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":160534,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q4fy24-29-fall-in-profits\/","url_meta":{"origin":171767,"position":4},"title":"Laurus Labs Ltd Q4FY24; 29% fall in Profits","author":"Chirag Gupta","date":"April 25, 2024","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/04\/image-42.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":163407,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q1fy25-52-fall-in-profits\/","url_meta":{"origin":171767,"position":5},"title":"Laurus Labs Ltd Q1FY25; 52% fall in Profits","author":"Chirag Gupta","date":"July 31, 2024","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-204.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/171767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=171767"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/171767\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/171768"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=171767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=171767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=171767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}